Cover image not available

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma :

Publication Data

Title The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma :
Contributors Joanna Picot, NIHR Evaluation, Trials and Studies Coordinating Centre, NIHR Health Technology Assessment Programme
Publisher Prepress Projects Ltd. on behalf of NETSCC, HTA
Publication date 2011
Publication location Perth
Language English

Descriptive Notes

"December 2011".
Publisher's no. : DOI: 10.3310/hta15410.
"Health Technology Assessment NIHR HTA Programme"--Cover.

Topics

Multiple myeloma :: Treatment
Multiple myeloma :: Chemotherapy :: Evaluation
Multiple myeloma :: Chemotherapy :: Cost-effectiveness
Antineoplastic agents

Catalogue Data

OBNB ID GBB210603
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99418

ISBD

P1053 xiii, 204 p.
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma :. Published by Prepress Projects Ltd. on behalf of NETSCC, HTA in 2011. Publication and catalogue information, links to buy online and reader comments.